177 related articles for article (PubMed ID: 24008424)
21. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
22. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
Yazdi AS; Ghoreschi K; Sander CA; Röcken M
Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
[TBL] [Abstract][Full Text] [Related]
23. Functional effects of GRM1 suppression in human melanoma cells.
Wangari-Talbot J; Wall BA; Goydos JS; Chen S
Mol Cancer Res; 2012 Nov; 10(11):1440-50. PubMed ID: 22798429
[TBL] [Abstract][Full Text] [Related]
24. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
[TBL] [Abstract][Full Text] [Related]
25. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
26. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
27. A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis.
Dunnill CJ; Ibraheem K; Mohamed A; Southgate J; Georgopoulos NT
Oncogene; 2017 May; 36(18):2515-2528. PubMed ID: 27869172
[TBL] [Abstract][Full Text] [Related]
28. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells.
Weiss MB; Abel EV; Mayberry MM; Basile KJ; Berger AC; Aplin AE
Cancer Res; 2012 Dec; 72(24):6382-92. PubMed ID: 23222305
[TBL] [Abstract][Full Text] [Related]
29. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
Zimmer L; Hillen U; Livingstone E; Lacouture ME; Busam K; Carvajal RD; Egberts F; Hauschild A; Kashani-Sabet M; Goldinger SM; Dummer R; Long GV; McArthur G; Scherag A; Sucker A; Schadendorf D
J Clin Oncol; 2012 Jul; 30(19):2375-83. PubMed ID: 22614973
[TBL] [Abstract][Full Text] [Related]
30. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
[TBL] [Abstract][Full Text] [Related]
31. The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells.
Slipicevic A; Jørgensen K; Skrede M; Rosnes AK; Trøen G; Davidson B; Flørenes VA
BMC Cancer; 2008 Sep; 8():276. PubMed ID: 18826602
[TBL] [Abstract][Full Text] [Related]
32. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
33. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
34. Induction of apoptosis signal-regulating Kinase 1 by E2F-1 may not be essential for E2F-1-mediated apoptosis in melanoma cells.
Dong YB; Phelps AM; Yang HL; Jamshidi-Parsian A; Chen C; Hao H; Gomez-Gutierrez JG; Zhou HS; McMasters KM
Tumour Biol; 2007; 28(2):111-22. PubMed ID: 17287612
[TBL] [Abstract][Full Text] [Related]
35. MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair.
Bhatia N; Xiao TZ; Rosenthal KA; Siddiqui IA; Thiyagarajan S; Smart B; Meng Q; Zuleger CL; Mukhtar H; Kenney SC; Albertini MR; Jack Longley B
J Invest Dermatol; 2013 Mar; 133(3):759-767. PubMed ID: 23096706
[TBL] [Abstract][Full Text] [Related]
36. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
37. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological Characteristics of BRAF V600E Mutated Melanomas in the Dalmatian Region of Croatia.
Bezić J; Kuret S; Vrbičić B; Smolić J; Borić I; Škifić I; Ledina D; Božić J
Acta Dermatovenerol Croat; 2019 Dec; 27(4):225-230. PubMed ID: 31969234
[TBL] [Abstract][Full Text] [Related]
39. Genomic and Clinicopathologic Characteristics of PRKAR1A-inactivated Melanomas: Toward Genetic Distinctions of Animal-type Melanoma/Pigment Synthesizing Melanoma.
Cohen JN; Yeh I; Mully TW; LeBoit PE; McCalmont TH
Am J Surg Pathol; 2020 Jun; 44(6):805-816. PubMed ID: 32118628
[TBL] [Abstract][Full Text] [Related]
40. Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation.
Mathieu V; Pirker C; Schmidt WM; Spiegl-Kreinecker S; Lötsch D; Heffeter P; Hegedus B; Grusch M; Kiss R; Berger W
Oncotarget; 2012 Apr; 3(4):399-413. PubMed ID: 22535842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
